Paper Details

  1. Home
  2. Paper Details

Japanese guidance for use of biologics for psoriasis (the 2019 version).

Author: , AbeMasatoshi, AsahinaAkihiko, EtohTakafumi, IgarashiAtsuyuki, ImafukuShinichi, KomineMayumi, MoritaAkimichi, NakagawaHidemi, OhtsukiMamitaro, SaekiHidehisa, SanoShigetoshi, TeruiTadashi, ToriiHideshi, WatanabeAkira, YotsuyanagiHiroshi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.

Overview

This guidance for dermatologists focuses on the selection of appropriate biologic therapies for psoriatic patients in Japan. It considers key factors including drug effects, safety, convenience, and cost, to assist physicians in making informed decisions about biologic therapy.
Paper Details　
Original Abstract of the Article :
As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti-tumor necrosis factor-α antibodies, became available in the field of dermatology in 2010, followed by ustekinumab, an anti-interleukin (IL)-12/IL-23p40 antibody, which was launched in Japan in 2011. Since 2015, three IL-1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/1346-8138.15196

データ提供：米国国立医学図書館（NLM）

Japanese Guidance for Use of Biologics for Psoriasis (the 2019 Version)

Psoriasis, a chronic skin condition, is often a challenging condition to manage. This study delves into the landscape of biologics, a class of medications used to treat psoriasis, in Japan. The authors provide a comprehensive overview of the available biologics and offer guidance on their appropriate use. The study discusses various factors to consider when selecting a biologic therapy, including drug effectiveness, safety, convenience for patients, and cost. The document aims to empower dermatologists in Japan to make informed decisions about biologic treatment for psoriasis patients.

Navigating the Desert of Biologic Therapies

The study emphasizes the importance of selecting the right biologic therapy for each patient, considering various factors such as disease severity, patient history, and treatment goals. The authors provide a detailed analysis of each biologic, including its mechanism of action, efficacy, safety profile, and convenience. The document outlines the need for personalized treatment plans and emphasizes the importance of sharing information with patients about their treatment options. Just as a desert traveler needs to carefully choose their route based on the terrain and available resources, so too must physicians select the right biologic therapy for each psoriasis patient.

A Guide for Dermatologists

This study provides valuable guidance for dermatologists in Japan, helping them to make informed decisions about the use of biologics for psoriasis. The document highlights the importance of personalized care, considering individual patient needs and preferences when selecting the most appropriate treatment option. It also emphasizes the importance of open communication with patients, ensuring they are fully informed about their treatment options and potential risks and benefits.

Dr.Camel's Conclusion

This study offers a comprehensive overview of the available biologics for psoriasis in Japan, providing valuable guidance for dermatologists. The document emphasizes the importance of personalized care, considering individual patient needs and preferences when selecting the most appropriate treatment option. It also highlights the importance of open communication with patients, ensuring they are fully informed about their treatment options and potential risks and benefits.

Date :
  1. Date Completed 2020-12-08
  2. Date Revised 2020-12-14
Further Info :

Pubmed ID

31916326

DOI: Digital Object Identifier

10.1111/1346-8138.15196

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.